Polycythemia vera is a complex and chronic hematologic disorder. Despite established treatment protocols, many patients experience persistent symptoms and inadequate disease control, particularly when resistant or intolerant to first-line therapies.

Myelofibrosis (MF) is a hematologic disorder characterized by splenomegaly, constitutional symptoms, ineffective hematopoiesis, and an increased risk of leukemic transformation.